137975-41-8 Usage
General Description
(3-Aminophenyl)(3,4-dihydro-1(2H)-quinolinyl)-methanone, also known as APDIQ, is a chemical compound with potential pharmacological significance. It is structurally categorized as an aryl ketone, with an aminophenyl and dihydroquinolinyl moiety attached to the carbonyl group. APDIQ has been studied for its potential as a psychoactive drug, particularly in the context of recreational use and abuse. Additionally, it has been investigated for its potential as a therapeutic agent for various medical conditions, including neurodegenerative disorders and psychiatric disorders. However, due to its psychoactive properties and potential for abuse, APDIQ is also of interest to law enforcement and regulatory agencies. As such, it is subject to legal restrictions in many jurisdictions.
Check Digit Verification of cas no
The CAS Registry Mumber 137975-41-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,7,9,7 and 5 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 137975-41:
(8*1)+(7*3)+(6*7)+(5*9)+(4*7)+(3*5)+(2*4)+(1*1)=168
168 % 10 = 8
So 137975-41-8 is a valid CAS Registry Number.
137975-41-8Relevant articles and documents
Orally active, nonpeptide vasopressin V2 receptor antagonists: A novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds
Ogawa, Hidenori,Yamashita, Hiroshi,Kondo, Kazumi,Yamamura, Yoshitaka,Miyamoto, Hisashi,Kan, Keizo,Kitano, Kazuyoshi,Tanaka, Michinori,Nakaya, Kenji,Nakamura, Shigeki,Mori, Toyoki,Tominaga, Michiaki,Yabuuchi, Youichi
, p. 3547 - 3555 (2007/10/03)
This paper describes a novel series of nonpeptide vasopressin V2 receptor antagonists. It has been demonstrated that the 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-benzazepines and 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-1,5-benzodiazepines show a high affinity for V2 (and V(1a)) receptors. Among the 1-[4-(benzoylamino)benzoyl]-2,3,4,5- 1H-benzazepine series, compounds with an alkylamino group on the benzazepine ring have been shown to have oral activity. A lipophilic group at the ortho position on the terminal benzoyl ring is important for both high V2 receptor affinity and oral activity. On the basis of these favorable properties, clinical testing of 31b has begun for use as an oral and iv aquaretic agent.
